Reviewing TriSalus Life Sciences (TLSI) and Its Peers

TriSalus Life Sciences (NASDAQ:TLSI) is one of 236 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its competitors? We will compare TriSalus Life Sciences to related companies based on the strength of its valuation, institutional ownership, risk, analyst recommendations, profitability, earnings and dividends.

Risk & Volatility

TriSalus Life Sciences has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, TriSalus Life Sciences’ competitors have a beta of 0.45, suggesting that their average stock price is 55% less volatile than the S&P 500.

Earnings & Valuation

This table compares TriSalus Life Sciences and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
TriSalus Life Sciences	$18.51 million	-$59.04 million	-1.67
TriSalus Life Sciences Competitors	$1.02 billion	$9.23 million	-17.23

TriSalus Life Sciences’ competitors have higher revenue and earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 48.0% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 32.8% of TriSalus Life Sciences shares are held by company insiders. Comparatively, 15.1% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for TriSalus Life Sciences and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	0	0	5	1	3.17
TriSalus Life Sciences Competitors	1883	4845	9091	264	2.48

TriSalus Life Sciences currently has a consensus target price of $12.50, suggesting a potential upside of 199.04%. As a group, “Surgical & medical instruments” companies have a potential upside of 14.96%. Given TriSalus Life Sciences’ stronger consensus rating and higher possible upside, equities research analysts clearly believe TriSalus Life Sciences is more favorable than its competitors.

Profitability

This table compares TriSalus Life Sciences and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-219.71%	N/A	-192.99%
TriSalus Life Sciences Competitors	-548.71%	-134.21%	-26.36%

Summary

TriSalus Life Sciences beats its competitors on 9 of the 13 factors compared.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.